0
     

Report Added
Report already added
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027

The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, and neurological diseases. However high cost of plasma products and the lack of sufficient reimbursements, increasing adoption of on-demand recombinant factors, and shortage of plasma for manufacturing plasma fractionation products are expected to restrain the growth of this market to a certain extent during the forecast period.

“The hospitals and clinicssegmentis expected to dominate the market during the forecast period.”

Based on end user, the plasma fractionation market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes. In 2021, the hospitals and clinics segment accounted for the largest share of the global plasma fractionation market. The large share of this segment is attributed the improving healthcare infrastructure and growth in the number of hospitals & clinics in the emerging and established econmies. Leading players in this market are collaborating with hospitals to raise awareness about the treatment of rare diseases using plasma products and carry out clinical trials with hospital collaboration.Such initiatives by companies and hospitals are expected to drive the demand for plasma products for the treatment of various rare and life-threatening diseases such as hemophilia, PID, and COVID-19.

“The pulmonology application segment will witness the highest growth intheplasma fractionation market.”

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the pulmonology segment is expected to register the highest CAGR during the forecast period. Immunoglobulins and protease inhibitors are the major plasma products used in the treatment of various respiratory diseases. Immunoglobulins are mainly used to prevent and treat upper and lower respiratory tract infections. In recent years, the use of protease inhibitors, such as alpha-1-antitrypsin, has increased significantly in the pulmonology segment, thus growing the market segment for pulmonology application significantly.

“North America will dominate the market during the forecast period.”

Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the leading players adopting various organic and inorganic growth strategies to strengthen their market positions. The expansion of fractionation plants with state-of-the-art technologies is a key growth strategy followed by major players in this market in the region. Leading players also focus on acquiring plasma collection centers to expand their presence in North America.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type -Tier 1: 37%, Tier 2: 23%,and Tier 3: 40%
•By Designation - C-level:32%, D-level:26%, and Others:42%
•By Region - North America:35%, Europe:25%, Asia Pacific:20%, Latin America: 12%, and the Middle East and Africa: 8%

List of Companies Profiled in the Report
•CSL (Australia)
•Grifols, S.A. (Spain)
•Shire (US)
•Octapharma AG (Switzerland)
•Kedrion S.P.A (Italy)
•LFB (France)
•Biotest AG (Germany)
•Sanquin (Netherlands)
•China Biologic Products Holdings Inc. (China)
•GC Pharma (Korea)
•Bio Products Ltd. (UK)
•Japan Blood Products Organization (Japan)
•Emergent BioSolutions (US)
•Shanghai Raas Blood Products Co., Ltd. (China)
•Intas Pharmaceuticals Ltd. (India)
•Bharat Serum Vaccines Limited (India)
•SK Plasma (Korea)
•Sichuan YuandaShuyang Pharmaceutical Co., Ltd. (China)
•KabaFusion (US)
•Centurion Pharma (Istanbul)
•ADMA Biologics, Inc. (US)
•PlasmaGenBioSciences Pvt. Ltd. (India)
•Virchow Biotech Private Limited (India)
•Fusion Healthcare (India)
•Hemarus Therapeutics Limited (India)

Research Coverage:
This report provides a detailed picture of the global plasma fractionationmarket. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user,and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total plasma fractionation market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
•Market Penetration: Comprehensive information on plasma fractionation offered by the top 25 players in the plasma fractionation market. The report analyses the plasma fractionation market by product,application, end user, and region.
•Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation across key geographic regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionationmarket.
•Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the plasma fractionationmarket.
Table of Contents

1INTRODUCTION29
1.1OBJECTIVES OF THE STUDY29
1.2MARKET DEFINITION29
1.2.1INCLUSIONS & EXCLUSIONS29
1.3MARKET SCOPE30
FIGURE 1PLASMA FRACTIONATION MARKET30
1.3.1YEARS CONSIDERED FOR THE STUDY31
1.4CURRENCY31
1.5LIMITATIONS31
1.6STAKEHOLDERS32
1.7SUMMARY OF CHANGES32
2RESEARCH METHODOLOGY33
2.1RESEARCH DATA33
FIGURE 2RESEARCH DESIGN33
2.1.1SECONDARY DATA33
2.1.2PRIMARY DATA34
FIGURE 3BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: PLASMA FRACTIONATION MARKET35
2.2MARKET ESTIMATION METHODOLOGY36
FIGURE 4PLASMA FRACTIONATION MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 202136
FIGURE 5MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202137
2.2.1INSIGHTS FROM PRIMARY EXPERTS38
FIGURE 6MARKET SIZE VALIDATION FROM PRIMARY SOURCES38
2.3MARKET GROWTH RATE PROJECTIONS39
FIGURE 7PLASMA FRACTIONATION MARKET (SUPPLY SIDE): CAGR PROJECTIONS40
FIGURE 8PLASMA FRACTIONATION MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS40
2.3.1DATA TRIANGULATION41
FIGURE 9DATA TRIANGULATION METHODOLOGY41
2.4RESEARCH ASSUMPTIONS42
2.4.1COVID-19 ASSUMPTIONS43
2.5RISK ANALYSIS43
3EXECUTIVE SUMMARY44
FIGURE 10PLASMA FRACTIONATION MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION)44
FIGURE 11PLASMA FRACTIONATION MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)45
FIGURE 12PLASMA FRACTIONATION MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)45
FIGURE 13GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET46
4PREMIUM INSIGHTS47
4.1PLASMA FRACTIONATION MARKET OVERVIEW47
FIGURE 14GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH47
4.2NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT & COUNTRY (2019)48
FIGURE 15IMMUNOGLOBULINS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 202148
4.3PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES49
FIGURE 16GERMANY TO REGISTER THE HIGHEST CAGR IN THE PLASMA FRACTIONATION MARKET DURING THE FORECAST PERIOD49
5MARKET OVERVIEW50
5.1INTRODUCTION50
5.1.1MARKET DYNAMICS50
FIGURE 17PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES50
5.2MARKET DYNAMICS51
TABLE 1PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS51
5.2.1MARKET DRIVERS52
5.2.1.1Growing use of immunoglobulins in various therapeutic areas52
TABLE 2ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG52
TABLE 3NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION
(AS OF 2020–2021)53
TABLE 4NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN THE UK53
5.2.1.2Rapidly growing geriatric population54
TABLE 5GERIATRIC POPULATION, BY REGION, 2000−205054
5.2.1.3Growing prevalence of respiratory diseases and AATD55
5.2.1.4New indications for plasma products55
5.2.2MARKET RESTRAINTS56
5.2.2.1High costs and limited reimbursements56
5.2.2.2Market disruption caused by recombinant alternatives56
5.2.3MARKET OPPORTUNITIES57
5.2.3.1Increased risk of communicable diseases57
5.2.3.2Rising prevalence of bleeding disorders57
FIGURE 18NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012–201857
TABLE 6NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 201858
5.2.4MARKET CHALLENGES58
5.2.4.1Reduced supply of plasma due to low donor turnout58
5.2.4.2Stringent government regulations59
5.3IMPACT ASSESSMENT OF PLASMA FRACTIONATION MARKET60
FIGURE 19SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE PLASMA FRACTIONATION MARKET60
5.4PRICING ANALYSIS61
TABLE 7AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY KEY PLAYER, 2021 (USD)61
TABLE 8AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY REGION, 2021 (USD)61
5.5IMPACT OF COVID-19 ON MARKET DYNAMICS62
5.5.1DRIVERS AND OPPORTUNITIES62
5.5.2RESTRAINTS AND CHALLENGES63
5.5.3CUMULATIVE GROWTH ANALYSIS63
5.6TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES64
FIGURE 20REVENUE SHIFT & NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS64
5.7VALUE CHAIN ANALYSIS64
FIGURE 21PROCEDURE OF PLASMA FRACTIONATION65
FIGURE 22VALUE CHAIN ANALYSIS OF THE PLASMA FRACTIONATION MARKET66
5.8SUPPLY CHAIN ANALYSIS66
FIGURE 23SUPPLY CHAIN ANALYSIS OF THE PLASMA FRACTIONATION MARKET67
5.9ECOSYSTEM ANALYSIS68
FIGURE 24ECOSYSTEM ANALYSIS OF THE PLASMA FRACTIONATION MARKET68
TABLE 9SUPPLY CHAIN ECOSYSTEM69
5.10PATENT ANALYSIS71
FIGURE 25PATENT APPLICATIONS FOR THE PLASMA FRACTIONATION MARKET, JANUARY 2012–MARCH 202271
TABLE 10INDICATIVE LIST OF PATENTS IN THE PLASMA FRACTIONATION MARKET72
5.11KEY CONFERENCES AND EVENTS IN 2022–202373
TABLE 11PLASMA FRACTIONATION MARKET: LIST OF CONFERENCES AND EVENTS73
5.12REGULATORY ANALYSIS74
5.12.1LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES74
5.12.2REGULATORY SCENARIO IN DIFFERENT REGIONS/COUNTRIES75
5.13PORTER’S FIVE FORCES ANALYSIS76
TABLE 12PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS76
5.13.1THREAT FROM NEW ENTRANTS77
5.13.2THREAT FROM SUBSTITUTES77
5.13.3BARGAINING POWER OF BUYERS77
5.13.4BARGAINING POWER OF SUPPLIERS78
5.13.5DEGREE OF COMPETITION78
5.14TECHNOLOGY ANALYSIS78
5.14.1COHN’S COLD ETHANOL PLASMA FRACTIONATION79
5.14.2GEL FILTRATION PLASMA FRACTIONATION79
5.14.3HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL79
5.14.4PLASMA FRACTIONATION BY AMMONIUM SULFATE79
5.15KEY STAKEHOLDERS AND BUYING CRITERIA80
FIGURE 26INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR
PLASMA FRACTIONATION PRODUCTS80
5.16KEY BUYING CRITERIA BY END USERS80
FIGURE 27BUYING CRITERIA OF END USERS80
6PLASMA FRACTIONATION MARKET, BY PRODUCT81
6.1INTRODUCTION82
TABLE 13PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION)82
6.2IMMUNOGLOBULINS82
TABLE 14IVIG VS. SCIG THERAPY83
TABLE 15PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)83
TABLE 16NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 17EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 18ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 19LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 20MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 21PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)85
6.2.1INTRAVENOUS IMMUNOGLOBULINS86
6.2.1.1IVIg holds the largest share of the immunoglobulins market86
TABLE 22INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS87
TABLE 23PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)88
TABLE 24NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 25EUROPE: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 26ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 27LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 28MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY,
2020–2027 (USD MILLION)89
6.2.2SUBCUTANEOUS IMMUNOGLOBULINS90
6.2.2.1Benefits of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market90
TABLE 29SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS90
TABLE 30PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)91
TABLE 31NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 32EUROPE: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 33ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 34LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 35MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY,
2020–2027 (USD MILLION)92
6.2.3OTHER IMMUNOGLOBULINS93
TABLE 36OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS93
TABLE 37PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,
BY REGION, 2020–2027 (USD MILLION)95
TABLE 38NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 39EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 40ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 41LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 42MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)97
6.3COAGULATION FACTOR CONCENTRATES97
TABLE 43PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)98
TABLE 44NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 45EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 46ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 47LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 48MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY,
2020–2027 (USD MILLION)99
TABLE 49PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)100
6.3.1FACTOR VIII100
6.3.1.1Factor VIII holds the largest share of the coagulation factor concentrates market100
TABLE 50FACTOR VIII OFFERED BY KEY MARKET PLAYERS100
TABLE 51PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION,
2020–2027 (USD MILLION)101
TABLE 52NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,
BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 53EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 54ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,
BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 55LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,
BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 56MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)103
6.3.2FACTOR IX103
6.3.2.1Rising number of hemophilic patients to drive the growth of this market103
TABLE 57FACTOR IX OFFERED BY KEY MARKET PLAYERS103
TABLE 58PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION,
2020–2027 (USD MILLION)104
TABLE 59NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX,
BY COUNTRY, 2020–2027 (USD MILLION)104
TABLE 60EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 61ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX,
BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 62LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX,
BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 63MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)106
6.3.3VON WILLEBRAND FACTOR106
6.3.3.1Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia106
TABLE 64VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS106
TABLE 65PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2020–2027 (USD MILLION)107
TABLE 66NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)107
TABLE 67EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)107
TABLE 68ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 69LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 70MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)108
6.3.4PROTHROMBIN COMPLEX CONCENTRATES109
6.3.4.1Advantages of PCC over fresh frozen plasma will support market growth in this segment109
TABLE 71PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS109
TABLE 72PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)109
TABLE 73NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 74EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 75ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 76LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)111
TABLE 77MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY,
2020–2027 (USD MILLION)111
6.3.5FIBRINOGEN CONCENTRATES111
6.3.5.1Safety profile, accuracy, and speed of administration are the key advantages of fibrinogen concentrates111
TABLE 78FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS111
TABLE 79PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,
BY REGION, 2020–2027 (USD MILLION)112
TABLE 80NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 81EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 82ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)113
TABLE 83LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)113
TABLE 84MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)113
6.3.6FACTOR XIII114
6.3.6.1Applications in treating rare bleeding disorders will contribute to the demand for factor XIII114
TABLE 85FACTOR XIII OFFERED BY KEY MARKET PLAYERS114
TABLE 86PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION,
2020–2027 (USD MILLION)114
TABLE 87NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,
BY COUNTRY, 2020–2027 (USD MILLION)114
TABLE 88EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)115
TABLE 89ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,
BY COUNTRY, 2020–2027 (USD MILLION)115
TABLE 90LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,
BY COUNTRY, 2020–2027 (USD MILLION)115
TABLE 91MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)116
6.3.7FACTOR XI116
6.3.7.1Growing demand for factor XI to treat bleeding disorders in patients to drive growth116
TABLE 92PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY REGION,
2020–2027 (USD MILLION)116
TABLE 93NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI,
BY COUNTRY, 2020–2027 (USD MILLION)117
TABLE 94EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)117
TABLE 95ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XI,
BY COUNTRY, 2020–2027 (USD MILLION)117
TABLE 96LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI,
BY COUNTRY, 2020–2027 (USD MILLION)118
TABLE 97MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)118
6.4ALBUMIN118
6.4.1RISING DEMAND FOR ALBUMIN AS AN ANTIOXIDANT TO DRIVE MARKET GROWTH118
TABLE 98ALBUMIN OFFERED BY KEY MARKET PLAYERS119
TABLE 99PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION,
2020–2027 (USD MILLION)120
TABLE 100NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN,
BY COUNTRY, 2020–2027 (USD MILLION)120
TABLE 101EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)120
TABLE 102ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN,
BY COUNTRY, 2020–2027 (USD MILLION)121
TABLE 103LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN,
BY COUNTRY, 2020–2027 (USD MILLION)121
TABLE 104MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)121
6.5PROTEASE INHIBITORS122
6.5.1RISING PREVALENCE OF COPD WILL DRIVE THE DEMAND FOR
PROTEASE INHIBITORS122
TABLE 105PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS122
TABLE 106PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION)123
TABLE 107NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)123
TABLE 108EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,
BY COUNTRY, 2020–2027 (USD MILLION)123
TABLE 109ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)124
TABLE 110LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)124
TABLE 111MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)124
6.6OTHER PLASMA PRODUCTS125
TABLE 112PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS,
BY REGION, 2020–2027 (USD MILLION)125
TABLE 113NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)125
TABLE 114EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)126
TABLE 115ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)126
TABLE 116LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)126
TABLE 117MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)127
7PLASMA FRACTIONATION MARKET, BY APPLICATION128
7.1INTRODUCTION129
TABLE 118PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION)129
7.2NEUROLOGY129
7.2.1RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH129
TABLE 119NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030130
TABLE 120PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY131
TABLE 121PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)131
TABLE 122NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)132
TABLE 123EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, 2020–2027 (USD MILLION)132
TABLE 124ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)132
TABLE 125LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)133
TABLE 126MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)133
7.3IMMUNOLOGY133
7.3.1INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS WILL DRIVE THE GROWTH OF THIS MARKET133
TABLE 127LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY134
TABLE 128DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASE134
TABLE 129PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION,
2013 VS. 2015135
TABLE 130PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY135
TABLE 131PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)136
TABLE 132NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)136
TABLE 133EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, 2020–2027 (USD MILLION)136
TABLE 134ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)137
TABLE 135LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)137
TABLE 136MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)137
7.4HEMATOLOGY138
7.4.1GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS138
TABLE 137NUMBER OF HEMOPHILIA PATIENTS (2012–2020)138
TABLE 138PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY139
TABLE 139PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)139
TABLE 140NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)139
TABLE 141EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)140
TABLE 142ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)140
TABLE 143LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)140
TABLE 144MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)141
7.5CRITICAL CARE141
7.5.1INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS141
TABLE 145PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE142
TABLE 146PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)142
TABLE 147NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)143
TABLE 148EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, 2020–2027 (USD MILLION)143
TABLE 149ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)143
TABLE 150LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)144
TABLE 151MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)144
7.6PULMONOLOGY144
7.6.1RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY144
TABLE 152PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY145
TABLE 153PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)145
TABLE 154NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)145
TABLE 155EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, 2020–2027 (USD MILLION)146
TABLE 156ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)146
TABLE 157LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)146
TABLE 158MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)147
7.7HEMATO-ONCOLOGY147
7.7.1RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS147
TABLE 159INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN’S LYMPHOMA, BY REGION, 2012−2018147
TABLE 160PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY148
TABLE 161PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)148
TABLE 162NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)148
TABLE 163EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, 2020–2027 (USD MILLION)149
TABLE 164ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)149
TABLE 165LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)149
TABLE 166MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)150
7.8RHEUMATOLOGY150
7.8.1INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY150
TABLE 167PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)150
TABLE 168NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)151
TABLE 169EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)151
TABLE 170ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)151
TABLE 171LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)152
TABLE 172MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)152
7.9OTHER APPLICATIONS152
TABLE 173PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS153
TABLE 174PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)153
TABLE 175NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)154
TABLE 176EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, 2020–2027 (USD MILLION)154
TABLE 177ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)154
TABLE 178LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)155
TABLE 179MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)155
8PLASMA FRACTIONATION MARKET, BY END USER156
8.1INTRODUCTION157
TABLE 180PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)157
8.2HOSPITALS & CLINICS157
8.2.1IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWING NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH157
TABLE 181PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)158
TABLE 182NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)158
TABLE 183EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)159
TABLE 184ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)159
TABLE 185LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, 2020–2027 (USD MILLION)159
TABLE 186MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)160
8.3CLINICAL RESEARCH LABORATORIES160
8.3.1INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET GROWTH160
TABLE 187PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION)161
TABLE 188NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)161
TABLE 189EUROPE: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)161
TABLE 190ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)162
TABLE 191LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, 2020–2027 (USD MILLION)162
TABLE 192MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)162
8.4ACADEMIC INSTITUTES163
8.4.1GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES163
TABLE 193PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)163
TABLE 194NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)164
TABLE 195EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, 2020–2027 (USD MILLION)164
TABLE 196ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)164
TABLE 197LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES BY COUNTRY, 2020–2027 (USD MILLION)165
TABLE 198MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)165
9PLASMA FRACTIONATION MARKET, BY REGION166
9.1INTRODUCTION167
TABLE 199PLASMA FRACTIONATION MARKET, BY REGION, 2020–2027 (USD MILLION)167
9.2NORTH AMERICA168
FIGURE 28NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT168
TABLE 200NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2020–2027 (USD MILLION)169
TABLE 201NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION)169
TABLE 202NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)169
TABLE 203NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)170
TABLE 204NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)170
TABLE 205NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION)170
9.2.1US171
9.2.1.1The US is the largest market for plasma fractionation products171
TABLE 206US: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION)171
TABLE 207US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)172
TABLE 208US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)172
TABLE 209US: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION)172
TABLE 210US: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION)173
9.2.2CANADA173
9.2.2.1Canada is one of the world’s highest per capita users of IVIg—
a key factor driving market growth173
TABLE 211CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MILLION)174
TABLE 212CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,
BY TYPE, 2020–2027 (USD MILLION)174
TABLE 213CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)175
TABLE 214CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2020–2027 (USD MILLION)175
TABLE 215CANADA: PLASMA FRACTIONATION MARKET, BY END USER,
2020–2027 (USD MILLION)175
9.3EUROPE176
TABLE 216EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2020–2027 (USD MILLION)176
TABLE 217EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2020–2027 (USD MI

Report Title: Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028

Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028

United Kingdom Restorative Dentistry Market, By Type (Anterior v/s Posterior), By Restoration Type (Direct v/s Indirect), By Product (Restorative Materials, Implants, Prosthetics, Restorative Equipment, Others), By End User (Hospitals & Clinics, Dental Laboratories, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Restorative Dentistry Market, By Type (Anterior v/s Posterior), By Restoration Type (Direct v/s Indirect), By Product (Restorative Materials, Implants, Prosthetics, Restorative Equipment, Others), By End User (Hospitals & Clinics, Dental Laboratories, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Renal Denervation Market, By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Micro-infusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Renal Denervation Market, By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Micro-infusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Oral Care Market, By Type (Toothpaste, Toothbrush, Mouthwashes/Rinses, Dental Accessories, Denture Products, Others), By Distribution Channel (Consumer Stores, Retail Pharmacies, Online Distribution, Dental Dispensaries), By End User (Dental Hospitals & Clinics v/s Homecare), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Oral Care Market, By Type (Toothpaste, Toothbrush, Mouthwashes/Rinses, Dental Accessories, Denture Products, Others), By Distribution Channel (Consumer Stores, Retail Pharmacies, Online Distribution, Dental Dispensaries), By End User (Dental Hospitals & Clinics v/s Homecare), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Medical Loupes Market, By Type (Flip-Up Loupes, Through-The-Lens (TTL) Loupes, Clip-On Loupes, Headband Mounted), By Lens Type (Galilean v/s Prismatic), By Distribution Channel (Offline v/s Online), By Application (Surgical, Dental, Others), By End User (Hospitals, Dental Clinics, Ambulatory Surgery Centers, Others), By Source (Domestic v/s Import), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Medical Loupes Market, By Type (Flip-Up Loupes, Through-The-Lens (TTL) Loupes, Clip-On Loupes, Headband Mounted), By Lens Type (Galilean v/s Prismatic), By Distribution Channel (Offline v/s Online), By Application (Surgical, Dental, Others), By End User (Hospitals, Dental Clinics, Ambulatory Surgery Centers, Others), By Source (Domestic v/s Import), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Glucometers Market, By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique (Invasive v/s Non-Invasive), By Type (Wearable v/s Non-Wearable), By Distribution Channel (Hospital Pharmacies, Retail Outlet, Online, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Home Care, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom Glucometers Market, By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique (Invasive v/s Non-Invasive), By Type (Wearable v/s Non-Wearable), By Distribution Channel (Hospital Pharmacies, Retail Outlet, Online, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Home Care, Others), By Region, Competition Forecast & Opportunities, 2027